Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry

[1]  R. Gelber,et al.  Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial. , 2017 .

[2]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[3]  Enzo Coviello,et al.  Estimating and Modeling Relative Survival , 2015 .

[4]  J. Ludvigsson,et al.  Review of 103 Swedish Healthcare Quality Registries , 2015, Journal of internal medicine.

[5]  Observational Studies: Getting Clear about Transparency , 2014, PLoS medicine.

[6]  R. Gelber,et al.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. , 2014, The Lancet. Oncology.

[7]  V. Tjan-Heijnen,et al.  Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. , 2013, European journal of cancer.

[8]  L. Moja,et al.  Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.

[9]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[10]  J. Bergh,et al.  Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden , 2011, Breast Cancer Research and Treatment.

[11]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Costantino,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Gelber,et al.  A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. , 2008, Clinical breast cancer.

[15]  C. Geyer,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Holmberg,et al.  Differences in Management of Older Women Influence Breast Cancer Survival: Results from a Population-Based Database in Sweden , 2006, PLoS medicine.

[17]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[18]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[19]  J. Ioannidis,et al.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[20]  Paul W Dickman,et al.  Regression models for relative survival , 2004, Statistics in medicine.

[21]  A. Goldhirsch,et al.  Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Umberto Veronesi,et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.

[23]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[24]  I. Smith.  New drugs for breast cancer , 2002, The Lancet.

[25]  W. Sauerbrei,et al.  Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Rutqvist,et al.  Undernotification of diagnosed cancer cases to the Stockholm Cancer Registry. , 1985, International journal of epidemiology.

[27]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[28]  F. Ederer,et al.  The relative survival rate: a statistical methodology. , 1961, National Cancer Institute monograph.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death , 2013 .

[31]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  D. Cox.  Regression Models and Life-Tables , 1972 .